Imlifidase for highly sensitized kidney transplant patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a drug called imlifidase, which may help clear the antibodies that make it hard for highly sensitized patients to receive a kidney from a deceased donor. If you qualify, this treatment could increase your chances of getting a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You are on the waiting list for a kidney transplant.
- You are considered highly sensitized, meaning your immune system has many antibodies that make finding a matching kidney difficult.
- You have at least one antibody that can be removed with the study drug, imlifidase.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This study looks at how memory B cells (a type of immune cell) relate to antibodies against HLA in people waiting for a kidney transplant. It aims to better understand immune responses, which could help improve transplant matching and outcomes.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This trial tests an experimental drug called om336 to lower antibodies that make it hard to receive a kidney transplant. It aims to help people who have been waiting a long time for a kidney due to high antibody levels.
This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.